We propose a coordinated and highly interactive program for the investigation of the immunology and immunotherapy of human cancer. Four project areas are proposed; each relates to the central theme of developing new means to utilize the immune system in the treatment of cancer patients. Project I will define and characterize immunological factors that can suppress tumor growth. Human monoclonal anti-idiotype antibodies and human lymphoid cell clones specific for human tumor-associated antigens will be developed and characterized. Project II will expand on previous findings that circulating immune complexes in cancer patients include complexes containing immunochemically definable tumor-associated antigens. The antigens will be further purified and characterized, and sensitive and specific immunoassays will be developed. Project III is a systematic study of the use of active specific immunotherapy for the treatment of malignant melanoma. Immunization with allogeneic and autologous tumor-cell vaccines will be extensively investigated. Host modification will be focused on the augmentation of tumor associated humoral immune responses by the ablation of cellular suppressor functions of the expansion of cellular helper functions. Project IV will focus on natural killer cells and their regulation in cancer patients. The effects of alloimmunization, interferon, or interleukin-2 therapy on NK- precursors and suppressors will be studied. These projects share many areas of technology, a common patient population, and a team of experienced investigators who are highly established in their respective fields.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
2P01CA012582-15A1
Application #
3092572
Study Section
(SRC)
Project Start
1977-07-01
Project End
1991-12-31
Budget Start
1987-04-01
Budget End
1987-12-31
Support Year
15
Fiscal Year
1987
Total Cost
Indirect Cost
Name
University of California Los Angeles
Department
Type
Schools of Medicine
DUNS #
119132785
City
Los Angeles
State
CA
Country
United States
Zip Code
90095
Dükel, Muzaffer; Streitfeld, W Scott; Tang, Tsz Ching Chloe et al. (2016) The Breast Cancer Tumor Suppressor TRIM29 Is Expressed via ATM-dependent Signaling in Response to Hypoxia. J Biol Chem 291:21541-21552
Kiyohara, Eiji; Hata, Keisuke; Lam, Stella et al. (2014) Circulating tumor cells as prognostic biomarkers in cutaneous melanoma patients. Methods Mol Biol 1102:513-22
Greenberg, Edward S; Chong, Kelly K; Huynh, Kelly T et al. (2014) Epigenetic biomarkers in skin cancer. Cancer Lett 342:170-7
Chiu, Connie G; Nakamura, Yoshitaka; Chong, Kelly K et al. (2014) Genome-wide characterization of circulating tumor cells identifies novel prognostic genomic alterations in systemic melanoma metastasis. Clin Chem 60:873-85
Faries, Mark B; Steen, Shawn; Ye, Xing et al. (2013) Late recurrence in melanoma: clinical implications of lost dormancy. J Am Coll Surg 217:27-34; discussion 34-6
Kidner, Travis B; Morton, Donald L; Lee, Delphine J et al. (2012) Combined intralesional Bacille Calmette-Guérin (BCG) and topical imiquimod for in-transit melanoma. J Immunother 35:716-20
Hoshimoto, Sojun; Shingai, Tatsushi; Morton, Donald L et al. (2012) Association between circulating tumor cells and prognosis in patients with stage III melanoma with sentinel lymph node metastasis in a phase III international multicenter trial. J Clin Oncol 30:3819-26
Hoshimoto, Sojun; Kuo, Christine T; Chong, Kelly K et al. (2012) AIM1 and LINE-1 epigenetic aberrations in tumor and serum relate to melanoma progression and disease outcome. J Invest Dermatol 132:1689-97
Faries, Mark B; Morton, Donald L (2012) Staging of regional nodes in pulmonary malignancies. Ann Surg Oncol 19:703-5
Hoshimoto, Sojun; Faries, Mark B; Morton, Donald L et al. (2012) Assessment of prognostic circulating tumor cells in a phase III trial of adjuvant immunotherapy after complete resection of stage IV melanoma. Ann Surg 255:357-62

Showing the most recent 10 out of 238 publications